How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Stroke Therapeutics Market
- By Therapeutic Approach: Thrombolytic Therapy, Antiplatelet Therapy, Anticoagulant Therapy, Neuroprotective Agents, Rehabilitation Therapy
- By Drug Class: Tissue Plasminogen Activators (tPA), Direct Oral Anticoagulants (DOACs), Platelet Aggregation Inhibitors, Statins, Calcium Channel Blockers
- By Stroke Type: Ischemic Stroke, Hemorrhagic Stroke, Transient Ischemic Attack (TIA)
- By Route of Administration: Intravenous, Oral, Intra-arterial, Subcutaneous
- By End User: Hospitals, Specialty Clinics, Rehabilitation Centers, Home Healthcare
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Thrombolytic Therapy leads By Therapeutic Approach at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 301 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.179 →
- 12 Company Profiles 17 players: SWOT & benchmarking p.187 →
Full report · locked preview
Everything inside the Stroke Therapeutics Market report
A complete, evidence-based study - 12 chapters and 126 sections covering market size, segmentation across 5 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Therapeutic Approach 5
Drug Class 5
Stroke Type 3
Route of Administration 4
End User 4
Companies profiled
Bayer AG
Boehringer Ingelheim GmbH
Stryker Corporation
Medtronic plc
Johnson & Johnson
Pfizer Inc.
Abbott Laboratories
Bristol-Myers Squibb Company
Novartis AG
Sanofi S.A.
Terumo Corporation
Penumbra Inc.
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Boehringer Ingelheim GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Stryker Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Bristol-Myers Squibb Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Novartis AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sanofi S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Terumo Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Penumbra Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →NeuroVasc Technologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Genentech
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Inc. (Roche)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →MediBeacon
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,183M by 2033 · 6.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Thrombolytic Therapy34.6
- Antiplatelet Therapy11.2
- Anticoagulant Therapy10.9
- Neuroprotective Agents22.5
- Rehabilitation Therapy20.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$866.0M → $1,482M · 6.9%
Europe$603.6M → $1,004M · 6.6%
Asia Pacific$551.1M → $830.1M · 5.3%
Latin America$341.1M → $573.2M · 6.7%
Middle East and Africa$262.4M → $405.6M · 5.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.952026
5.972027
5.982028
5.982029
6.002030
6.022031
6.042032
6.052033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Bayer AG23.0
- Boehringer Ingelheim GmbH19.5
- Stryker Corporation7.5
- Medtronic plc6.6
- Johnson & Johnson8.9
- Pfizer Inc.6.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapeutic Approach19.9%
Drug Class14.2%
Stroke Type37.4%
Route of Administration14.0%
End User14.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.5
- Europe23.4
- Asia Pacific19.3
- Latin America13.3
- Middle East and Africa9.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Bayer AG | 75 | 76 | 89 | 89 | 80 | 81 | 82 |
| Boehringer Ingelheim GmbH | 89 | 82 | 69 | 86 | 68 | 78 | 79 |
| Stryker Corporation | 76 | 87 | 88 | 79 | 66 | 85 | 80 |
| Medtronic plc | 67 | 68 | 61 | 58 | 79 | 80 | 69 |
| Johnson & Johnson | 72 | 75 | 68 | 65 | 56 | 51 | 65 |
| Pfizer Inc. | 53 | 48 | 69 | 70 | 57 | 58 | 59 |
| Abbott Laboratories | 52 | 45 | 52 | 53 | 44 | 63 | 52 |
| Bristol-Myers Squibb Company | 41 | 51 | 55 | 42 | 43 | 56 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Bayer AG
- Boehringer Ingelheim GmbH
- Stryker Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Bayer AG | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Boehringer Ingelheim GmbH | ✓ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Stryker Corporation | ◐ | ◐ | ✓ | ◐ | ◐ | ✓ |
| Medtronic plc | − | − | ◐ | ◐ | ✓ | ✓ |
| Johnson & Johnson | ✓ | ✓ | ◐ | ◐ | − | − |
| Pfizer Inc. | ◐ | − | ◐ | − | ◐ | − |
| Abbott Laboratories | − | − | ◐ | ◐ | − | − |
| Bristol-Myers Squibb Company | − | ◐ | ◐ | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Bayer AG82
2Stryker Corporation80
3Boehringer Ingelheim GmbH79
4Medtronic plc69
5Johnson & Johnson65
6Pfizer Inc.59
7Abbott Laboratories52
8Bristol-Myers Squibb Company48
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Bayer AGBoehringer Ingelheim GmbHStryker Corporation
Challenger1
Strong scale, closing on the leaders.
Medtronic plc
Contender2
Focused players with pockets of strength.
Johnson & JohnsonPfizer Inc.
Niche2
Specialists in a single segment or region.
Abbott LaboratoriesBristol-Myers Squibb Company
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapeutic Approach in North America, then scale across Stroke Therapeutics Market — a $107M beachhead inside a $1.45B market.
Beachhead (SOM)$107Mobtainable near-term
Serviceable (SAM)$577Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Thrombolytic Therapy
Best fit — highest urgency & budget in Therapeutic Approach.
Economic buyer77 fit
Antiplatelet Therapy
Strong fit — clear ROI and a fast path to value.
End user68 fit
Anticoagulant Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapeutic Approach in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Stroke Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel30%
Digital / self-serve18%
Marketplaces10%
Positioning & messaging
§GTM 2 · p.194 →For Therapeutic Approach leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Stroke Therapeutics Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified24%
Evaluation12%
Closed-won6%
$20.9KCAC
$116KLTV
5.6:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Stroke Therapeutics Market is a durable-growth opportunity — $1.96B by 2033, compounding at 6.5%.
TAM · 2025$1.18Btoday
TAM · 2033$1.96Bforecast
CAGR6.5%2027–2033
Cumulative$13.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.96BTotal addressable market
SAM$795MServiceable available market
SOM$130MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.5% CAGR
Demand compounds through 2033, outpacing GDP across Therapeutic Approach.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapeutic Approach moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.96BLarge & growingTAM by 2033 at 6.5% CAGR
$795MServiceable nowreachable with today’s model
$130MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.53BBear4.2% CAGR
$1.96BBase6.5% CAGR
$2.50BBull8.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Stroke Therapeutics Market — a $7.99B market by 2033. Plan: grow share from 8.1% to 16.2%.
Market size · 2033$7.99Btotal addressable
Market CAGR6.4%2027–2033
Target share16.2%from 8.1% today
Revenue ambition$1.30Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.1% | 16.2% | On track |
| Revenue | $592M | $1.30B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 36.8% | 38.9% | At risk |
| Customer retention | 91.8% | 96.6% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapeutic Approach
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Class capability
A defensible second engine — invest in Drug Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapeutic Approach share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $160M capacity & capability investment
- Greenlight bolt-on M&A in Drug Class
- Authorise North America expansion plan
- Fund R&D program for Therapeutic Approach leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Stroke Therapeutics Market conversation — a $6.79B market you can size, segment and defend in minutes.
Market size · 2033$6.79Btotal opportunity
Growth3.6%CAGR to 2033
Addressable buyers1,430+accounts in scope
Typical ROI6.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapeutic Approach
Goal Grow share in Therapeutic Approach
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.7×return on cost, year one
< 2 mopayback period
$43K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Bayer AGBoehringer Ingelheim GmbHStryker CorporationMedtronic plcJohnson & JohnsonPfizer Inc.Abbott LaboratoriesBristol-Myers Squibb Company+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Stroke Therapeutics Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Stroke Therapeutics Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Stroke Testing Biomarkers Market
Market size, share, segmentation and regional forecast.
$982M market · 2025 base year
View reportStroke Telemedicine Services Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportStroke-physiological Saline Solution Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportStroke Management Device Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportStroke Diagnostics Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportStrip Warmer Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportStrip Test Handler Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportStrip Readers Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportStretch Mark Treatment Product Market
Market size, share, segmentation and regional forecast.
$569M market · 2025 base year
View reportStretch Marks Removal Products Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportStretch Marks Lightening Treatment Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportStretch Mark Removal Products Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.